Company Filing History:
Years Active: 2014
Title: Syed Kashmiri: Innovator in Humanized Antibodies
Introduction
Syed Kashmiri is a notable inventor based in North Potomac, MD (US). He has made significant contributions to the field of biotechnology, particularly in the development of humanized monoclonal antibodies. His work focuses on enhancing the efficacy and safety of therapeutic antibodies used in cancer treatment.
Latest Patents
Syed Kashmiri holds a patent for "Framework residue substituted humanized COL-1 antibodies and their use." This patent describes humanized COL-1 monoclonal antibodies that maintain CEA binding affinity compared to a parent antibody. The invention also includes antibodies with reduced immunogenicity, achieved by substituting framework residues with those from a homologous human sequence. The patent outlines methods for using these antibodies in the detection or treatment of CEA-expressing tumors or cells in subjects. Additionally, a kit containing these humanized COL-1 antibodies is also disclosed.
Career Highlights
Syed Kashmiri is affiliated with the National Institutes of Health, a component of the US Department of Health & Human Services. His work at this prestigious institution has allowed him to contribute to groundbreaking research in the field of immunology and cancer therapy.
Collaborations
Throughout his career, Syed has collaborated with esteemed colleagues, including Jeffrey Schlom and Eduardo Agustin Padlan. These collaborations have furthered the development of innovative therapeutic solutions in the medical field.
Conclusion
Syed Kashmiri's contributions to the field of humanized antibodies exemplify the importance of innovation in medical research. His work not only advances scientific knowledge but also holds the potential to improve treatment options for patients with cancer.